Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study
المؤلفون المشاركون
Kääb, Stefan
Lackermair, Korbinian
Schuhmann, Christoph G.
Kubieniec, Michaela
Riesinger, Lisa M.
Klier, Ina
Stocker, Thomas J.
Estner, Heidi L.
Fichtner, Stephanie
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-06-27
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
Wearable cardioverter defibrillator (WCD) therapy is feasible and safe in patients as a transient protection against sudden cardiac death (SCD).
However, the impact of WCD therapy on quality of life (QoL) has not been studied.
Methods.
In our single-centre study, 109 consecutive patients with a prescription of WCD were retrospectively analysed.
Quality of life has been assessed by a standardized questionnaire (EQ-5D-3L, modified).
Additionally, clinical baseline and follow-up data and recorded arrhythmic episodes were evaluated.
Results.
Mean WCD therapy time was 56.2 (± 42.4) days, with a daily wear time of 19.7 (± 5) hours.
A total of 3441 arrhythmia episodes were detected.
Of these, 27 (1%) were adequate but did not require shock therapy.
Likewise, no inadequate shock therapy occurred.
WCD therapy negatively affected quality of life: 43% of patients reported mental health issues.
37% reported pain or discomfort.
Self-care, usual activities, and mobility were restricted in 17%, 48%, and 36%, respectively.
29% were afraid of receiving shock therapy, and 48% suffered from sleep disturbance.
However, 64% indicated having felt safe during WCD therapy.
Accordingly, average quality of life was rated 70/100 points.
Conclusion.
In our cohort, no SCD was prevented by WCD therapy.
In contrast, in this preliminary study quality of life was reduced.
Thus, careful recommendation of WCD therapy for high risk patients should be considered.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Lackermair, Korbinian& Schuhmann, Christoph G.& Kubieniec, Michaela& Riesinger, Lisa M.& Klier, Ina& Stocker, Thomas J.…[et al.]. 2018. Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study. BioMed Research International،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1127656
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Lackermair, Korbinian…[et al.]. Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study. BioMed Research International No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1127656
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Lackermair, Korbinian& Schuhmann, Christoph G.& Kubieniec, Michaela& Riesinger, Lisa M.& Klier, Ina& Stocker, Thomas J.…[et al.]. Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1127656
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1127656
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر